83324-56-5

Basic information

• Product Name: 3-[(E)-3,7-Dimethyl-2,6-octadienyl]-2,4-dihydroxy-6-methylbenzaldehyde
• Synonyms: 3-[(E)-3,7-Dimethyl-2,6-octadienyl]-2,4-dihydroxy-6-methylbenzaldehyde;Colletorin B
• CAS NO: 83324-56-5
• Molecular Formula: C₁₈H₂₄O₃
• Molecular Weight: 0
• Mol File: 83324-56-5.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-[(E)-3,7-Dimethyl-2,6-octadienyl]-2,4-dihydroxy-6-methylbenzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[(E)-3,7-Dimethyl-2,6-octadienyl]-2,4-dihydroxy-6-methylbenzaldehyde(83324-56-5)
• EPA Substance Registry System: 3-[(E)-3,7-Dimethyl-2,6-octadienyl]-2,4-dihydroxy-6-methylbenzaldehyde(83324-56-5)

Safety Data

• Hazardous Substances Data: 83324-56-5(Hazardous Substances Data)

Upstream product

• 6138-90-5 trans-geranyl bromide 
• 487-69-4 2,4-dihydroxy-6-methylbenzaldehyde 
• 6652-71-7 4-Acetoxy-2-hydroxy-6-methyl-benzaldehyd 

Relevant articles and documents

African trypanosomiasis: Synthesis & SAR enabling novel drug discovery of ubiquinol mimics for trypanosome alternative oxidase

African trypanosomiasis is a parasitic disease affecting 5000 humans and millions of livestock animals in sub-Saharan Africa every year. Current treatments are limited, difficult to administer and often toxic causing long term injury or death in many pati

NOVEL DIHYDROXYBENZENE DERIVATIVES AND ANTIPROTOZOAL AGENT COMPRISING SAME AS ACTIVE INGREDIENT

Novel compounds below are useful for preventing or treating diseases caused by protozoans. At least one of a compound represented by Formula (I) (wherein, X represents a hydrogen atom or a halogen atom; R1 represents a hydrogen atom; R2 represents a hydrogen atom or a C1-7 alkyl group; R3 represents -CHO, -C(=O)R5, -COOR5 (wherein R5 represents a C1-7 alkyl group), -CH2OH or -COOH; and R4 represents a C1-16 alkyl group having one or more substituents on a terminal carbon atom and/or non-terminal carbon atom(s), a C2-16 alkenyl group having one or more substituents on a terminal carbon atom and/or non-terminal carbon atom(s), or a C2-16 alkynyl group having one or more substituents on a terminal carbon atom and/or non-terminal carbon atom(s)), an optical isomer thereof, and a pharmaceutically acceptable salt is used.